Arcturus’ proprietary unlocked nucleomonomer agent (UNA) Oligomer™ technology can be used to make all types of RNA medicines more stable, safe and specific.
UNA nucleotides can be incorporated into either DNA or RNA using standard automated synthesis procedures. UNAs have a similar structure to natural nucleic acids so do not change RNA function or tertiary structure. In partnered clinical trials, RNA medicines incorporating UNAs have been shown to be safe and effective in human patients.
UNAs are not recognized by the immune system so do not stimulate an immune response and are not broken down as quickly as natural RNA. Therefore RNA medicines incorporating UNAs cause less toxicity, have less off-target effects, are more potent and have a longer half-life than regular RNA medicines.
May 30, 2017
Arcturus Therapeutics to Receive Up to $3 Million from Cystic Fibrosis Foundation Therapeutics to Advance a Novel LUNAR-Formulated mRNA CFTR Therapeutic
August 23, 2017
Pictures by Ernst and Young (Finalists for the Entrepreneur Of The Year 2017 Award® in San Diego)
August 9, 2017
Arcturus Therapeutics in the list of Cystic Fibrosis Key Companies